App-Quantinova.ai

Early gastrointestinal dysfunction is predictive of faster progression in Parkinson’s disease

M. Camacho - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Enhanced cingulate activity while anticipating pain – evidence for altered ‘top down’ processing of pain in PD

S. Martin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Evaluating the clinical utility of the Parkinson’s KinetiGraph (PKG™) in the remote management of Parkinson’s disease

T. Dominey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluation of a driving questionnaire to facilitate awareness of issues that could compromise driving ability in a person with Parkinson’s disease

J. Price - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluation of bradykinesia in Parkinson’s disease using a computerised evolutionary algorithm

R. Newby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Expanding the clinical phenotype of BPAN: A case report

M. Boca - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Neurodegeneration with brain iron accumulation 5

N/A

Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease

E. Wong - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Factors predicting patient satisfaction with botulinum toxin treatment in cervical dystonia patients who have been treated for a year

V. Misra - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cervical dystonia

Botox

Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?

S. Del Din - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Functional connectivity changes in relation to dopaminergic decline in Parkinson’s over time: A resting-state fMRI and 11C-PE2I PET imaging study

W. Li - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Genome-wide association studies of motor and cognitive progression in Parkinson’s disease

M. Tan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Higher self-rated obsessive-compulsion in functional compared with organic dystonia

R. Newby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Identifying delirium and it prevalence in idiopathic Parkinson’s disease

R. Lawson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease

L. Scourfield - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)

M. Alsahab - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Impulsive-Compulsive Behaviour disorders: A longitudinal study in de-novo in Parkinson’s disease patients

L. Ricciardi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Incidence of Parkinson’s disease: Pooled analysis of six high-quality incidence studies with long-term follow-up

A. Macleod - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

P. Korlipara - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

entacapone

Instrumented gait analysis identifies potential predictors for Parkinson’s disease converters

S. Del Din - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Interaction between MAPT H1 and APOE4 in early Parkinson’s Disease

C. Lambert - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts